Catalog No.
KDD72801
Description
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human ACVR2A has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Bimagrumab in the sample competitively binds to the pre-coated protein with biotin-labeled Bimagrumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Bimagrumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Bimagrumab concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
125 - 4,000 ng/mL
Sensitivity
97.28 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision |
Inter-Assay Precision |
||||
|
Sample |
1 |
2 |
3 |
1 |
2 |
3 |
|
n |
16 |
16 |
16 |
24 |
24 |
24 |
|
Mean (ng/mL) |
1992.7 |
394.7 |
183.8 |
1817.1 |
458.8 |
255.4 |
|
Standard deviation |
369.5 |
23.3 |
22.4 |
284.5 |
40.1 |
33.6 |
|
CV (%) |
18.5 |
5.9 |
12.2 |
15.7 |
8.7 |
13.1 |
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.
Alternative Names
BYM338, CAS: 1356922-05-8
Background
Bimagrumab is a monoclonal anti-ActRIIA/IIB antibody that targets ActRIIA and ActRIIB simultaneously. Native ActRIIA and ActRIIB are both mediators of signaling from several TGFβ superfamily members such as activins, myostatin, and GDF11. Hence, pan-blockade by Bimagrumab achieves greater effect than a monoclonal antibody against either receptor alone, i.e. monotherapy with anti-ActRIIA antibody or anti-ActRIIB antibody. Bimagrumab has been explored as a therapy for sporadic inclusion body myositis, primary sarcopenia, and muscle wasting associated with chronic obstructive pulmonary disease.
For research use only. Not for human or drug use.
